Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

For the past three decades, the use of genomics to inform drug discovery and development
pipelines has generated both excitement and scepticism. Although earlier efforts …

Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Background BCR-ABL is a constitutively activated tyrosine kinase that causes chronic
myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Abstract Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and
antiangiogenesis via signaling through a common receptor interferon alpha receptor …

Background Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …